Movement Alert｜CSPC PHARMA Falls 3.01% in Regular Trading, Innovative Drug Sector Pullback Ahead of ESMO Data Readout

Market Focus

3 hours ago

On October 8, CSPC PHARMA fell 3.01% in regular trading, trading at 9.52 Hong Kong dollars with turnover of 376 million Hong Kong dollars. The decline came as the broader innovative drug sector pulled back ahead of key clinical data presentations.

The company recently announced that eight oncology clinical trial updates will be presented at the European Society for Medical Oncology Congress in Madrid from October 23 to 27, with two selected as late-breaking abstracts covering breast, lung, gastric, liver, colorectal, and pancreatic cancers. However, market attention is focused on whether ESMO clinical data will meet expectations, while renewed overseas interest rate expectations have pressured innovative drug valuations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1113451181"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113451181\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113451181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 13:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113451181","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC PHARMA Falls 3.01% in Regular Trading, Innovative Drug Sector Pullback Ahead of ESMO Data Readout","media":"Market Focus","content":"<p><p>On October 8, CSPC PHARMA fell 3.01% in regular trading, trading at 9.52 Hong Kong dollars with turnover of 376 million Hong Kong dollars. The decline came as the broader innovative drug sector pulled back ahead of key clinical data presentations.</p><p>The company recently announced that eight oncology clinical trial updates will be presented at the European Society for Medical Oncology Congress in Madrid from October 23 to 27, with two selected as late-breaking abstracts covering breast, lung, gastric, liver, colorectal, and pancreatic cancers. However, market attention is focused on whether ESMO clinical data will meet expectations, while renewed overseas interest rate expectations have pressured innovative drug valuations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC PHARMA Falls 3.01% in Regular Trading, Innovative Drug Sector Pullback Ahead of ESMO Data Readout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC PHARMA Falls 3.01% in Regular Trading, Innovative Drug Sector Pullback Ahead of ESMO Data Readout\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-08 13:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 8, CSPC PHARMA fell 3.01% in regular trading, trading at 9.52 Hong Kong dollars with turnover of 376 million Hong Kong dollars. The decline came as the broader innovative drug sector pulled back ahead of key clinical data presentations.</p><p>The company recently announced that eight oncology clinical trial updates will be presented at the European Society for Medical Oncology Congress in Madrid from October 23 to 27, with two selected as late-breaking abstracts covering breast, lung, gastric, liver, colorectal, and pancreatic cancers. However, market attention is focused on whether ESMO clinical data will meet expectations, while renewed overseas interest rate expectations have pressured innovative drug valuations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1113451181","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113451181","pubTimestamp":1791435719,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 8, CSPC PHARMA fell 3.01% in regular trading, trading at 9.52 Hong Kong dollars with turnover of 376 million Hong Kong dollars. The decline came as the broader innovative drug sector...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势提醒|石药集团常规交易下跌3.01%，ESMO数据公布前创新药板块回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On October 8, CSPC PHARMA fell 3.01% in regular trading, trading at 9.52 Hong Kong dollars with turnover of 376 million Hong Kong dollars. The decline came as the broader innovative drug sector pulled back ahead of key clinical data presentations.The company recently announced that eight oncology clinical trial updates will be presented at the European Society for Medical Oncology Congress in Madrid from October 23 to 27, with two selected as late-breaking abstracts covering breast, lung, gastric, liver, colorectal, and pancreatic cancers. However, market attention is focused on whether ESMO clinical data will meet expectations, while renewed overseas interest rate expectations have pressured innovative drug valuations.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}